Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
Multiplen Choice
Identifyn thenchoicenthatnbestncompletesnthenstatementnornanswersnthenquestion.
_ 1.n Nursenpractitionern prescriptiven authorityn isnregulatedn by:
A. Then Nationaln Counciln ofnStatenBoardsnofnNursing
B. Then U.S.nDrugn Enforcementn Administration
C. Then StatenBoardnofnNursingn forn eachnstate
D. Then StatenBoardn ofnPharmacy
_ 2.n Physiciann Assistantn (PA)nprescriptiven authorityn isnregulatedn by:
A. Then Nationaln Counciln ofnStatenBoardsnofnNursing
B. Then U.S.nDrugn Enforcementn Administration
C. Then Staten Boardn ofnNursing
D. Then StatenBoardn ofnMedicaln Examiners
_ 3.nClinicaln judgmentn innprescribingn includes:
A. Factoringn inn thencostnton thenpatientn ofnthen medicationn prescribed
B. Alwaysn prescribingn thennewestnmedicationn availablen fornthendiseasenprocess
C. Handingn outn drugnsamplesn tonpoornpatients
D. Prescribingn allngenericn medicationsn toncutncosts
_ 4.n Criterian fornchoosingn anneffectiven drugn fornandisordern include:
A. Askingn thenpatientn whatndrugntheynthinkn wouldn worknbestnfornthem
B. Consultingnnationallyn recognizedn guidelinesn forndiseasenmanagement
C. Prescribingn medicationsnthatn arenavailablenasnsamplesn beforen writingn anprescription
D. Followingn U.S.nDrugn Enforcementn Administrationn (DEA)n guidelinesn forn
prescribing
_ 5.n Nursenpractitionern practicen maynthriven undernhealth-caren reformn duento:
A. Thendemonstratednabilitynofnnursenpractitionersntoncontrolncostsnandnimprovenpatientno
utcomes
B. Thenfactnthatnnursen practitionersn willnbenablentonpracticenindependently
C. Thenfactnthatnnursenpractitionersnwillnhavenfullnreimbursementnundernhealth-
carenreform
D. Then abilityn tonshiftn accountabilityn fornMedicaidn tonthen statenlevel
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
Chaptern 1:n Then Rolenofn then Nursen Practitionernasn Prescribern
Answern Section
MULTIPLEn CHOICE
1. ANS:n C PTS:nnn 1
2. ANS:n D PTS:nnn 1
3. ANS:n A PTS:nnn 1
4. ANS:n B PTS:nnn 1
5. ANS:n A PTS:nnn 1
Chaptern 2:n Reviewn ofn Basicn Principlesn ofnPharmacology
Multiplen Choice
Identifyn thenchoicenthatnbestncompletesnthenstatementnornanswersnthenquestion.
_
1.n Anpatient’sn nutritionaln intaken andnlabnworknreflectsn hypoalbuminemia.n Thisn is
criticaln tonprescribingn because:
n
A. Distributionn ofndrugsn tontargetn tissuen maynbenaffected
B. Then solubilityn ofnthendrugn willn notnmatchn then siten ofnabsorption
C. Theren willn benlessn freen drugn availablentongeneraten anneffect
D. Drugsn boundn tonalbuminn arenreadilyn excretedn bynthen kidney
_ 2.n Drugsn thatn haven ansignificantn first-passn effect:
A. Mustnbengivenn bynthenenteraln (oral)n routen only
B. Bypassnthenhepaticncirculation
C. Arenrapidlyn metabolizedn bynthenlivern andn maynhaven littlen ifnanyn desiredn action
D. Arenconvertedn bynthen livern tonmoren activen andnfat-solublen forms
_ 3.n Then routen ofnexcretionn ofnanvolatilen drugnwilln likelyn be:
A. Thenkidneys
B. Thenlungs
C. Thenbilen andnfeces
D. Thenskin
_
4.nMedroxyprogesteronen(DeponProvera)nisnprescribednIMntoncreatenanstoragenrese
rvoirnofnthendrug.n Storagen reservoirs:
A. Assurenthatnthendrugnwilln reachnitsnintendedn targetn tissue
B. Arenthen reasonnforn givingn loadingn doses
C. Increasen then lengthnofntimen andrugn isn availablen andn active
D. Arenmostncommonn inncollagenn tissues
_ 5.n Then NPnchoosesn tongiven cephalexinn everyn 8nhoursn basednonnknowledgen ofn then drug’s:
A. Propensityn tongontonthen targetn receptor
B. Biologicalnhalf-life
C. Pharmacodynamics
D. Safetynandnsideneffects
_
6.nAzithromycinndosingnrequiresnthenfirstnday’sndosenbentwicenthosenofnthenothern4nd
aysnofnthenprescription.nThisn isn consideredn anloadingn dose.nAnloadingn dose:
A. Rapidlyn achievesn drugnlevelsn innthentherapeuticn range
B. Requiresn fourn tonfiven half-livesn tonattain
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
C. Isninfluencednbynrenaln function
D. Isndirectlyn relatedn tonthen drugncirculatingn tonthen targetn tissues
_
7.nThenpointninntimenonnthendrugnconcentrationncurventhatnindicatesnthenfirstnsignnofna
therapeuticneffectn isn the:
n
A. Minimumnadverseneffectnlevel
B. Peaknofnaction
C. Onsetnofnaction
D. Therapeuticnrange
_ 8.n Phenytoinn requiresn antroughn leveln bendrawn.n Peaknandntroughn levelsn arendone:
A. Whennthendrugnhasnanwidentherapeuticn range
B. Whennthen drugnwilln benadministerednfornanshortn timen only
C. Whenntheren isn anhighn correlationn betweennthen dosenandnsaturationn ofnreceptornsites
D. Tondeterminenifn andrugnisn innthen therapeuticn range
_
9.n Anlaboratorynresultn indicatesn thenpeaknleveln fornandrugn isnaboven thenmini
mumn toxicnconcentration.n Thisn meansn thatn the:
A.Concentrationn willn producentherapeuticn effects
B.Concentrationn willn producenannadversen response
C.Timen betweenndosesnmustn benshortened
D.Durationn ofnactionn ofnthendrugn isntoonlong
_ 10.n Drugsn thatnarenreceptornagonistsn mayndemonstraten whatn property?
A. Irreversiblen bindingn tonthen drugnreceptornsite
B. Up-regulationn withnchronicn use
C. Desensitizationn orndown-regulationn withn continuousnuse
D. Inversen relationshipn betweenndrugnconcentrationn andndrugnaction
_ 11.n Drugsn thatn arenreceptornantagonists,n suchnasnbetanblockers,n mayncause:
A. Down-regulationn ofnthendrugnreceptor
B. Annexaggeratedn responsenifnabruptlyndiscontinued
C. Partialn blockaden ofntheneffectsn ofnagonistndrugs
D. Annexaggeratedn responsen toncompetitiven drugnagonists
_ 12.n Factorsnthatnaffectn gastricn drugnabsorptionninclude:
A. Livernenzymenactivity
B. Protein-bindingn propertiesn ofnthendrugnmolecule
C. Lipidn solubilityn ofnthendrug
D. Abilityn tonchewnandnswallow
_ 13.n Drugsnadministeredn vianintravenousn (IV)nroute:
A. Needntonbenlipidn solublen innorderntonbeneasilyn absorbed
B. Beginn distributionn inton then bodynimmediately
C. Areneasilynabsorbednifntheynarennonionized
D. Maynusen pinocytosisn tonbenabsorbed
_
14.nWhennanmedicationnisnaddedntonanregimennfornansynergisticneffect,nthencombinedn
effectnofnthendrugsn is:
A. Then sumn ofntheneffectsn ofneachndrugnindividually
B. Greatern thann thensumn ofnthen effectsn ofneachndrugnindividually
C. Lessnthann theneffectn ofneachn drugnindividually
D. Notnpredictable,nasnitn variesn withn eachnindividual
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo n n n n n
_ 15.n Whichn ofnthen followingn statementsn aboutn bioavailabilityn isn true?
A. Bioavailabilitynissuesnarenespeciallynimportantnforndrugsnwithnnarrowntherapeuticnr
angesn ornsustainedn releasen mechanisms.
B. Alln brandsn ofnandrugnhaven then samen bioavailability.
C. Drugsnthatnarenadministerednmorenthannoncenandaynhavengreaternbioavailabilitynthannd
rugsn givenn oncen daily.
D. Combiningn annactiven drugn withn anninertn substancen doesnnotn affectn bioavailability.
_ 16.nWhichnofnthenfollowingnstatementsnaboutnthenmajorndistributionnbarriersn(blood-brainnornfetal-
placental)n isn true?
n
A. Waternsolublen andnionizedn drugsncrossnthesenbarriersn rapidly.
B. Then blood-brainn barriern slowsn thenentryn ofnmanyn drugsn inton andn fromn brainn cells.
C. Then fetal-placentaln barriern protectsn thenfetusn fromn drugsntakennbynthenmother.
D. Lipidn solublen drugsn donnotnpassnthesenbarriersn andnarensafen fornpregnantn women.
_
17.nDrugsnarenmetabolizednmainlynbynthenlivernvianPhasenInornPhasenIInreactions.nThenpu
rposenofbothnofnthesen typesn ofn reactionsn isn to:
A. Inactivaten prodrugsn beforen theyncannbenactivatedn byntargetn tissues
B. Changen thendrugsn sontheyncanncrossnplasman membranes
C. Changen drugnmoleculesn tonanformn thatn annexcretoryn organn cannexcrete
D. Makenthesen drugsn moren ionizednandnpolarn tonfacilitaten excretion
_ 18.n Oncentheynhaven beennmetabolizedn bynthen liver,n thenmetabolitesn maynbe:
A. Morenactiven thannthenparentndrug
B. Lessnactiven thannthenparentndrug
C. Totallyn “deactivated”n sonthatntheynarenexcretednwithoutn anyneffect
D. Allnofnthenabove
_
19.n Alln drugsn continuen ton actninn then bodynuntiln theyn aren changedn ornexcreted.n Then
abilitynofn thenbodyntonexcreten drugsn vian thenrenaln systemn wouldn benincreasedn by:
A. Reducedn circulationn andn perfusionn ofnthen kidney
B. Chronicn renalndisease
C. Competitionn forn antransportn siten bynanothern drug
D. Unbindingn annonvolatilen drugnfromnplasmanproteins
_ 20.n Steadynstatenis:
A. Then pointn onnthendrugn concentrationn curven whenn absorptionn exceedsnexcretion
B. Whennthen amountn ofndrugn inn thenbodynremainsn constant
C. Whennthen amountn ofndrugninn thenbodynstaysn belown thenMTC
D. Allnofnthenabove
_ 21.nTwondifferentn painn medsn arengivenn togethern forn painn relief.n Then drug-drugn interactionn is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
_ 22.n Actionsn takenntonreducen drug-
drugn interactionn problemsn includenalln ofnthen followingnEXCEPT:
A. Reducingn then dosenofnonenofnthen drugs
B. Schedulingntheirn administrationnatndifferentn times
C. Prescribingn anthirdn drugn toncounteractn thenadversen reactionn ofnthen combination
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
Multiplen Choice
Identifyn thenchoicenthatnbestncompletesnthenstatementnornanswersnthenquestion.
_ 1.n Nursenpractitionern prescriptiven authorityn isnregulatedn by:
A. Then Nationaln Counciln ofnStatenBoardsnofnNursing
B. Then U.S.nDrugn Enforcementn Administration
C. Then StatenBoardnofnNursingn forn eachnstate
D. Then StatenBoardn ofnPharmacy
_ 2.n Physiciann Assistantn (PA)nprescriptiven authorityn isnregulatedn by:
A. Then Nationaln Counciln ofnStatenBoardsnofnNursing
B. Then U.S.nDrugn Enforcementn Administration
C. Then Staten Boardn ofnNursing
D. Then StatenBoardn ofnMedicaln Examiners
_ 3.nClinicaln judgmentn innprescribingn includes:
A. Factoringn inn thencostnton thenpatientn ofnthen medicationn prescribed
B. Alwaysn prescribingn thennewestnmedicationn availablen fornthendiseasenprocess
C. Handingn outn drugnsamplesn tonpoornpatients
D. Prescribingn allngenericn medicationsn toncutncosts
_ 4.n Criterian fornchoosingn anneffectiven drugn fornandisordern include:
A. Askingn thenpatientn whatndrugntheynthinkn wouldn worknbestnfornthem
B. Consultingnnationallyn recognizedn guidelinesn forndiseasenmanagement
C. Prescribingn medicationsnthatn arenavailablenasnsamplesn beforen writingn anprescription
D. Followingn U.S.nDrugn Enforcementn Administrationn (DEA)n guidelinesn forn
prescribing
_ 5.n Nursenpractitionern practicen maynthriven undernhealth-caren reformn duento:
A. Thendemonstratednabilitynofnnursenpractitionersntoncontrolncostsnandnimprovenpatientno
utcomes
B. Thenfactnthatnnursen practitionersn willnbenablentonpracticenindependently
C. Thenfactnthatnnursenpractitionersnwillnhavenfullnreimbursementnundernhealth-
carenreform
D. Then abilityn tonshiftn accountabilityn fornMedicaidn tonthen statenlevel
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
Chaptern 1:n Then Rolenofn then Nursen Practitionernasn Prescribern
Answern Section
MULTIPLEn CHOICE
1. ANS:n C PTS:nnn 1
2. ANS:n D PTS:nnn 1
3. ANS:n A PTS:nnn 1
4. ANS:n B PTS:nnn 1
5. ANS:n A PTS:nnn 1
Chaptern 2:n Reviewn ofn Basicn Principlesn ofnPharmacology
Multiplen Choice
Identifyn thenchoicenthatnbestncompletesnthenstatementnornanswersnthenquestion.
_
1.n Anpatient’sn nutritionaln intaken andnlabnworknreflectsn hypoalbuminemia.n Thisn is
criticaln tonprescribingn because:
n
A. Distributionn ofndrugsn tontargetn tissuen maynbenaffected
B. Then solubilityn ofnthendrugn willn notnmatchn then siten ofnabsorption
C. Theren willn benlessn freen drugn availablentongeneraten anneffect
D. Drugsn boundn tonalbuminn arenreadilyn excretedn bynthen kidney
_ 2.n Drugsn thatn haven ansignificantn first-passn effect:
A. Mustnbengivenn bynthenenteraln (oral)n routen only
B. Bypassnthenhepaticncirculation
C. Arenrapidlyn metabolizedn bynthenlivern andn maynhaven littlen ifnanyn desiredn action
D. Arenconvertedn bynthen livern tonmoren activen andnfat-solublen forms
_ 3.n Then routen ofnexcretionn ofnanvolatilen drugnwilln likelyn be:
A. Thenkidneys
B. Thenlungs
C. Thenbilen andnfeces
D. Thenskin
_
4.nMedroxyprogesteronen(DeponProvera)nisnprescribednIMntoncreatenanstoragenrese
rvoirnofnthendrug.n Storagen reservoirs:
A. Assurenthatnthendrugnwilln reachnitsnintendedn targetn tissue
B. Arenthen reasonnforn givingn loadingn doses
C. Increasen then lengthnofntimen andrugn isn availablen andn active
D. Arenmostncommonn inncollagenn tissues
_ 5.n Then NPnchoosesn tongiven cephalexinn everyn 8nhoursn basednonnknowledgen ofn then drug’s:
A. Propensityn tongontonthen targetn receptor
B. Biologicalnhalf-life
C. Pharmacodynamics
D. Safetynandnsideneffects
_
6.nAzithromycinndosingnrequiresnthenfirstnday’sndosenbentwicenthosenofnthenothern4nd
aysnofnthenprescription.nThisn isn consideredn anloadingn dose.nAnloadingn dose:
A. Rapidlyn achievesn drugnlevelsn innthentherapeuticn range
B. Requiresn fourn tonfiven half-livesn tonattain
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo
n n n n n
C. Isninfluencednbynrenaln function
D. Isndirectlyn relatedn tonthen drugncirculatingn tonthen targetn tissues
_
7.nThenpointninntimenonnthendrugnconcentrationncurventhatnindicatesnthenfirstnsignnofna
therapeuticneffectn isn the:
n
A. Minimumnadverseneffectnlevel
B. Peaknofnaction
C. Onsetnofnaction
D. Therapeuticnrange
_ 8.n Phenytoinn requiresn antroughn leveln bendrawn.n Peaknandntroughn levelsn arendone:
A. Whennthendrugnhasnanwidentherapeuticn range
B. Whennthen drugnwilln benadministerednfornanshortn timen only
C. Whenntheren isn anhighn correlationn betweennthen dosenandnsaturationn ofnreceptornsites
D. Tondeterminenifn andrugnisn innthen therapeuticn range
_
9.n Anlaboratorynresultn indicatesn thenpeaknleveln fornandrugn isnaboven thenmini
mumn toxicnconcentration.n Thisn meansn thatn the:
A.Concentrationn willn producentherapeuticn effects
B.Concentrationn willn producenannadversen response
C.Timen betweenndosesnmustn benshortened
D.Durationn ofnactionn ofnthendrugn isntoonlong
_ 10.n Drugsn thatnarenreceptornagonistsn mayndemonstraten whatn property?
A. Irreversiblen bindingn tonthen drugnreceptornsite
B. Up-regulationn withnchronicn use
C. Desensitizationn orndown-regulationn withn continuousnuse
D. Inversen relationshipn betweenndrugnconcentrationn andndrugnaction
_ 11.n Drugsn thatn arenreceptornantagonists,n suchnasnbetanblockers,n mayncause:
A. Down-regulationn ofnthendrugnreceptor
B. Annexaggeratedn responsenifnabruptlyndiscontinued
C. Partialn blockaden ofntheneffectsn ofnagonistndrugs
D. Annexaggeratedn responsen toncompetitiven drugnagonists
_ 12.n Factorsnthatnaffectn gastricn drugnabsorptionninclude:
A. Livernenzymenactivity
B. Protein-bindingn propertiesn ofnthendrugnmolecule
C. Lipidn solubilityn ofnthendrug
D. Abilityn tonchewnandnswallow
_ 13.n Drugsnadministeredn vianintravenousn (IV)nroute:
A. Needntonbenlipidn solublen innorderntonbeneasilyn absorbed
B. Beginn distributionn inton then bodynimmediately
C. Areneasilynabsorbednifntheynarennonionized
D. Maynusen pinocytosisn tonbenabsorbed
_
14.nWhennanmedicationnisnaddedntonanregimennfornansynergisticneffect,nthencombinedn
effectnofnthendrugsn is:
A. Then sumn ofntheneffectsn ofneachndrugnindividually
B. Greatern thann thensumn ofnthen effectsn ofneachndrugnindividually
C. Lessnthann theneffectn ofneachn drugnindividually
D. Notnpredictable,nasnitn variesn withn eachnindividual
, Test Bank for Pharmacotherapeutics for Nurse
n n n n n n
Practitioner Prescribers 3rd Edition by Woo n n n n n
_ 15.n Whichn ofnthen followingn statementsn aboutn bioavailabilityn isn true?
A. Bioavailabilitynissuesnarenespeciallynimportantnforndrugsnwithnnarrowntherapeuticnr
angesn ornsustainedn releasen mechanisms.
B. Alln brandsn ofnandrugnhaven then samen bioavailability.
C. Drugsnthatnarenadministerednmorenthannoncenandaynhavengreaternbioavailabilitynthannd
rugsn givenn oncen daily.
D. Combiningn annactiven drugn withn anninertn substancen doesnnotn affectn bioavailability.
_ 16.nWhichnofnthenfollowingnstatementsnaboutnthenmajorndistributionnbarriersn(blood-brainnornfetal-
placental)n isn true?
n
A. Waternsolublen andnionizedn drugsncrossnthesenbarriersn rapidly.
B. Then blood-brainn barriern slowsn thenentryn ofnmanyn drugsn inton andn fromn brainn cells.
C. Then fetal-placentaln barriern protectsn thenfetusn fromn drugsntakennbynthenmother.
D. Lipidn solublen drugsn donnotnpassnthesenbarriersn andnarensafen fornpregnantn women.
_
17.nDrugsnarenmetabolizednmainlynbynthenlivernvianPhasenInornPhasenIInreactions.nThenpu
rposenofbothnofnthesen typesn ofn reactionsn isn to:
A. Inactivaten prodrugsn beforen theyncannbenactivatedn byntargetn tissues
B. Changen thendrugsn sontheyncanncrossnplasman membranes
C. Changen drugnmoleculesn tonanformn thatn annexcretoryn organn cannexcrete
D. Makenthesen drugsn moren ionizednandnpolarn tonfacilitaten excretion
_ 18.n Oncentheynhaven beennmetabolizedn bynthen liver,n thenmetabolitesn maynbe:
A. Morenactiven thannthenparentndrug
B. Lessnactiven thannthenparentndrug
C. Totallyn “deactivated”n sonthatntheynarenexcretednwithoutn anyneffect
D. Allnofnthenabove
_
19.n Alln drugsn continuen ton actninn then bodynuntiln theyn aren changedn ornexcreted.n Then
abilitynofn thenbodyntonexcreten drugsn vian thenrenaln systemn wouldn benincreasedn by:
A. Reducedn circulationn andn perfusionn ofnthen kidney
B. Chronicn renalndisease
C. Competitionn forn antransportn siten bynanothern drug
D. Unbindingn annonvolatilen drugnfromnplasmanproteins
_ 20.n Steadynstatenis:
A. Then pointn onnthendrugn concentrationn curven whenn absorptionn exceedsnexcretion
B. Whennthen amountn ofndrugn inn thenbodynremainsn constant
C. Whennthen amountn ofndrugninn thenbodynstaysn belown thenMTC
D. Allnofnthenabove
_ 21.nTwondifferentn painn medsn arengivenn togethern forn painn relief.n Then drug-drugn interactionn is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
_ 22.n Actionsn takenntonreducen drug-
drugn interactionn problemsn includenalln ofnthen followingnEXCEPT:
A. Reducingn then dosenofnonenofnthen drugs
B. Schedulingntheirn administrationnatndifferentn times
C. Prescribingn anthirdn drugn toncounteractn thenadversen reactionn ofnthen combination
